A protein that makes skin cancer cells more invasive

#1 VENTURE CLIENT PLATFORM

A protein that makes skin cancer cells more invasive

A potential new treatment method for melanoma skin cancer

Fluoride-free chocolate toothpaste

Minoxidil nanoparticles based anti-baldness technology fights against alopecia

Exclusive interview for SPINOFF.COM with Prof. (Emeritus) Aharon Gedanken, Kanbar Laboratory for Nanomaterials, Bar-Ilan University (BIUNI), about the technology that will help to grow hair on a bald surface using nanoparticles of minoxidil

This minoxidil based anti-baldness technology is a real breakthrough in the fight against alopecia. The team of professional scientists, under the strict supervision of Prof. Aharon Gedanken from the Department of Chemistry at Bar Ilan University in Israel, is now in the process of technology development. Such nanoparticle-based technology aims hair follicle, targeting at utilizing these interactions for therapeutic purposes, delivering functionalized particles selectively to the hair follicles or even to specific skin compartments and cell populations. Particle-based material targeting of hair follicles may include deposition of active minoxidil compounds in the follicular reservoir, targeting of active compounds to specific compartments within the follicular duct, e.g., sebaceous gland, stem cell region, or even targeting of specific cell populations such as perifollicular antigen-presenting cells. Professor Gedanken is sure that it will have a great success in the cosmetology because nobody tried to solve it at particle level before.  

by
10 hours ago

Thirty Madison: rebuilding the healthcare experience for consumers

Thirty Madison, the parent company of Keeps, announces a $15.25 million Series A funding round co-led by Maveron and Northzone with participation from Greycroft, Steadfast Venture Capital, First Round, ERA, HillCour and Two River. Additional investors include Divya Gugnani, co-founder of Wander Beauty, and Ben Cogan, co-founder & co-CEO of Hubble Contacts, as well as several other prominent individuals from the consumer and healthcare spaces. This brings the company’s total funding to $22.75 million. Thirty Madison will use funds from the Series A round to continue growing their first brand Keeps, the only service that offers a comprehensive solution focused on male pattern baldness. 

by
10 hours ago

DECOMER produces eco-friendly polymers for alternative packaging

Waste from plastics has gained worldwide attention in recent years as scientists find massive accumulation in oceans, microplastics contaminating our food supply, and pollution spreading to distant ecosystems. As a result, countries are rapidly moving to ban plastics, particularly single use, and multinational companies are pouring billions of dollars into R&D to find replacements. Decomer Technology co-founders Mart Salumäe and Kelly Kangur, out of Estonia’s University of Tartu, has developed a new plant-based material to replace a plastics in a huge range of single-use products in food industry, agriculture, pharmaceuticals, detergents, etc.

10 hours ago

Mission Bio: transforming single-Cell DNA analysis

FUSION GENOMICS: a new era in pathogen sequencing

GenomeDx improves cancer and urology patient care

The pioneering cell-programming therapies

OxStem Ltd. was co-founded by the leading British scientists and chemists Professors Dame Kay Davies, Stephen G. Davies and Angela J. Russell. OxStem has developed cell programming therapies that could treat a range of usually age-related conditions – dementia, heart failure, macular degeneration, diabetes and cancer. The company has already established four subsidiaries each with a specific disease focus: OxStem Oncology, OxStem Neuro and OxStem Ocular and OxStem Cardio. With the new technology, it is possible to identify new types of drugs that can re-program or stimulate existing endogenous cells, replacing previously deceased or dormant cellular processes. The novelty contains in the unique combination of know-how in large-scale stem cell culture. This enables phenotypic screening and preclinical models, together with proven medicinal chemistry expertise. OxStem aims to expand a collection of drug candidates and reactivate these innate repair processes as a therapeutic paradigm applicable to a wide range of degenerative diseases.

by
35 days ago

Developing treatments for rare genetic diseases

The rare disease therapy was developed by Modis Therapeutics. This company is based on Columbia University research. Modis Therapeutics was formed through a collaboration with academic experts in mitochondrial biology to develop disease-modifying therapies for rare genetic diseases. The company completed a series A financing with investments from F-Prime Capital Partners, OrbiMed, Aceras Life Sciences, and Osage University Partners. The company has assembled a management team with deep experience in the development of high-impact products for serious diseases at leading biotech and pharmaceutical companies. Modis is a dedicated team, passionate about bringing novel therapies to patients with uncommon diseases.

by
35 days ago

Smart Bandages will protect from microbes

The 'smart' bandage that tracks the healing of the wound beneath it monitors the level of activity of the patient and, if necessary, sends the data back to the doctor, was developed by scientists from Swansea University's Institute of Life Science.

by
35 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

#1 VENTURE CLIENT PLATFORM